Tagged Articles

AndroGel 1.62% 27 articles

Study blames surge in testosterone drug sales on “disease mongering” marketing

Testosterone replacement drugs are surging in popularity in Australia and Canada, thanks to slick promotional campaigns and “disease mongering” by pharmaceutical companies, said the author of a new study published in the Medical Journal of Australia (MJA). In the study, David Handelsman, director of the ANZAC Research Institute at the University of Sydney, examined patterns in testosterone drug prescribing in Australia from 1992 to 2010. He found total expenditures on testosterone prescriptions more than doubled in that time period after taking into account inflation and population growth, yet there was no correlating increase in the number of approved uses for ... Read More

Testim maker poised to expand its share of men’s health market

Bolstered by soaring demand for testosterone replacement products, a deal with GlaxoSmithKline to market its top drug Testim, and now favorable results of a new drug study to treat penile curvature, things are looking up for Auxilium Pharmaceuticals. Reuters reports that shares of Auxilium, a small drug company based in Malvern, Pennsylvania, shot up 17 percent Monday on news that two late-stage trials indicated its drug Xiaflex reduced curvature of the penis by more than 30 percent in men with Peyronie’s Disease, a condition caused when excessive collagen protein deposits create curvature and sometimes painful erections. Xiaflex is already approved ... Read More

Testosterone wars heat up as Testim maker allies with GlaxoSmithKline

Testim manufacturer Auxilium Pharmaceuticals Inc. of Malvern, Pennsylvania, has entered a partnership with GlaxoSmithKline to drive up sales of the testosterone drug, the companies announced this week. Testim is a topical gel containing one percent testosterone, prescribed as a hormone-replacement therapy for men with clinically low testosterone levels and the physical slow-down that generally accompanies “low T,” as the condition is sometimes called. Testim and other testosterone replacement therapies are also sought after by men who take the drug for recreational purposes. The effects of excessive testosterone in men are virtually the same as taking steroids, with increased muscle mass ... Read More

Drugmakers credit Androgel and Testim for first-quarter profit surge

The market for testosterone replacement drugs is booming, with no signs of easing in the future, market analysts say. Abbott Laboratories, the maker of Androgel 1.62% and Androgel 1% and Auxilium Pharmaceuticals, which makes Testim 1%, are aggressively marketing their testosterone drugs to millions of men in the U.S. with low testosterone levels, and those efforts are paying off. Sales of testosterone replacement drugs hit $1.6 billion in 2011, up 133 percent in just four years. According to data compiled by Bloomberg analysts, 5.6 million prescriptions were written for testosterone replacement therapies last year and sales are expected to triple ... Read More

NJ doctor may lose license for inappropriate testosterone replacement and painkiller prescriptions

The New Jersey Attorney General’s Office has moved to suspend the medical license of a doctor who, investigators allege, indiscriminately prescribed potent testosterone replacement drugs such as Androgel in addition to powerful prescription pain medications, including OxyContin and Roxicodone when they weren’t appropriate and necessary for patients to take. According to Newark’s Star-Ledger, Dr. Roger Lallemand Jr. wrote thousands of such prescriptions for patients visiting the three offices he maintained in Old Bridge and Asbury Park, New Jersey. The doctor told one patient, an undercover investigator with the U.S. Drug Enforcement Administration, that he offered testosterone drugs to all of ... Read More

Appeals judges side with Big Pharma in Androgel case

A U.S. appeals court in Atlanta sided with Big Pharma in an April ruling, allowing “pay-for-delay” arrangements between brand-name and generic drug manufacturers. At the center of this ruling was the testosterone drug Androgel, a blockbuster drug made by Brussels-based Solvay (now Abbott Pharmaceuticals) that brought in $594 million in 2010 and promises explosive growth in the future as more and more men turn to it for its sexually restorative effects. Solvay was originally granted a 17-year patent in 2003, which barred other drugmakers from developing a generic version of the topical gel until 2015. However, three drug companies challenged ... Read More

Testosterone drug use building to an epidemic of health problems, doctors fear

AndroGel, Testim and other topical testosterone gel products were designed to restore healthy levels of functioning in men suffering from diminished bone and muscle mass, depression, weakened libido and other symptoms associated with low testosterone levels, or “Low T”. But now doctors are worried the testosterone drugs – coveted by many men for their sexual enhancement properties — are quickly creating another hormone-replacement health crisis in the United States. Bloomberg reports that AndroGel manufacturer Abbott Laboratories and other drug companies making and marketing testosterone drugs are offering to help some 14 million American men whose testosterone levels may be lower ... Read More